TBio-4101
- Generic Name
- TBio-4101
Turnstone Biologics Restructures to Focus on TIL Therapy, Extends Cash Runway into 2026
• Turnstone Biologics is prioritizing its clinical program, TIDAL-01, a Selected TIL therapy, and streamlining operations to extend its cash runway into the second quarter of 2026.
• The company is reducing its workforce by approximately 60% as part of a strategic realignment to focus on clinical development and manufacturing efforts.
• Initial Phase 1 data from the STARLING trial supports the biological hypothesis for TIL selection, showcasing a complete response in a heavily pre-treated MSS-CRC patient.
• Leadership transitions include Ines Verdon assuming leadership of clinical activities and Michael Fitch overseeing manufacturing, with other changes in finance and operations.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath